Short Interest in Estrella Immunopharma, Inc. (NASDAQ:ESLA) Rises By 8.5%

Estrella Immunopharma, Inc. (NASDAQ:ESLA) saw a significant growth in short interest in July. As of July 15th, there was short interest totalling 19,100 shares, a growth of 8.5% from the June 30th total of 17,600 shares. Based on an average trading volume of 17,600 shares, the short-interest ratio is currently 1.1 days. Approximately 0.2% of the company’s stock are short sold.

Institutional Trading of Estrella Immunopharma

An institutional investor recently bought a new position in Estrella Immunopharma stock. ATW Spac Management LLC bought a new position in Estrella Immunopharma, Inc. (NASDAQ:ESLA) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 40,000 shares of the company’s stock, valued at approximately $44,000. ATW Spac Management LLC owned about 0.11% of Estrella Immunopharma as of its most recent filing with the Securities and Exchange Commission. 0.35% of the stock is currently owned by institutional investors.

Estrella Immunopharma Stock Down 22.4 %

Shares of NASDAQ ESLA traded down $0.45 during midday trading on Tuesday, reaching $1.56. 164,140 shares of the company’s stock were exchanged, compared to its average volume of 60,249. Estrella Immunopharma has a 52-week low of $0.81 and a 52-week high of $33.00. The business’s fifty day moving average price is $1.14 and its two-hundred day moving average price is $1.12.

Estrella Immunopharma (NASDAQ:ESLA) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.01) earnings per share (EPS) for the quarter.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.